PatientsLikeMe is the world’s largest integrated community, health management, and real‑world data platform that lets members share personal stories, symptoms, treatments, and outcomes. A growing community of more than 830,000 people across over 2,900 conditions contributes self‑reported data used to monitor symptoms, quantify outcomes, and provide peer support. The platform aggregates these real‑world data to support care delivery, scientific research, consumer engagement, and clinical trials, and the company cites more than 100 studies in peer‑reviewed medical and scientific journals. PatientsLikeMe plans to expand its support and empowerment of people managing significant health conditions and to accelerate partnerships with care delivery organizations, health plans, employers, pharmacies, PBMs, life‑sciences organizations, and government sponsors. The company is entering a new phase of growth as an independent, venture‑backed organization and will use new funding to scale those efforts. The recent financing is intended to broaden the platform’s capacity for patient engagement, research, and care‑management solutions. PatientsLikeMe operates a personalized digital platform that collects and aggregates patient-generated health data to give patients real-world context for decision-making and outcome improvement. The platform is used by more than 500,000 people to track and share information about roughly 2,700 conditions. More than 40 pharmaceutical companies and numerous government organizations have collaborated with PatientsLikeMe and used its data for research and product development. The company has published more than 100 research studies based on patient-generated health data. PatientsLikeMe is led by CEO Martin Coulter and was co-founded by Ben and Jamie Heywood and Jeff Cole. Through a new strategic partnership with iCarbonX the company plans to apply next-generation biological measures and machine learning, with iCarbonX providing multi-omics characterization services.

Total raised

$126M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2021